RT Journal Article
T1 Total and Fetal Circulating Cell-Free DNA, Angiogenic, and Antiangiogenic Factors in Preeclampsia and HELLP Syndrome.
A1 Muñoz-Hernández, Rocío
A1 Medrano-Campillo, Pablo
A1 Miranda, Maria L
A1 Macher, Hada C
A1 Praena-Fernández, Jose Manuel
A1 Vallejo-Vaz, Antonio J
A1 Dominguez-Simeon, María J
A1 Moreno-Luna, Rafael
A1 Stiefel, Pablo
K1 HELLP syndrome
K1 angiogenic factors
K1 antiangiogenic factors
K1 blood pressure
K1 cell-free DNA
K1 hypertension
K1 hypertension in pregnancy
K1 maternal-fetal adverse outcomes
K1 preeclampsia.
AB Preeclampsia (PE) is a hypertensive disorder of pregnancy characterized by hypertension and proteinuria. The HELLP syndrome is the most severe form of PE. The aim of the present study was to determine different potential biomarkers that may help us perform an early diagnosis of the disease, assess on the severity of the disease, and/or predict maternal or fetal adverse outcomes. We measured serum levels of total and fetal circulating cell-free DNA (cfDNA), soluble endoglin, soluble form of vascular endothelial growth factor receptor, and placental growth factor in a healthy control group of pregnant women (n = 26), patients with mild (n = 37) and severe PE (n = 25), and patients with HELLP syndrome (n = 16). We observed a gradual and strong relationship between all the biomarkers mentioned and the range of severity of PE, with the highest levels in patients with HELLP syndrome. Nevertheless, only the values of total cfDNA were able to significantly differentiate severe PE and HELLP syndrome (20957 ± 2784 vs. 43184 ± 8647 GE/ml, P = 0.01). Receiver operating characteristic (ROC) curves were constructed (i) for the healthy group with respect to the groups with PE and (ii) for patients with PE with respect to the group with HELLP syndrome; sensitivity and specificity values at different cutoff levels were calculated in each case. The maximum ROC area under the curve value for PE and HELLP syndrome (with respect to controls) was 0.91 (P  The measured biomarkers of cell damage, angiogenesis, and antiangiogenesis may reflect the severity of PE, with higher levels in patients who develop HELLP syndrome. In addition, these biomarkers may also help predict adverse fetal and maternal outcomes.
YR 2017
FD 2017
LK http://hdl.handle.net/10668/10996
UL http://hdl.handle.net/10668/10996
LA en
DS RISalud
RD Apr 7, 2025